Patient-specific quality assurance on a Varian Halcyon linear accelerator using a PTW Octavius 4D device.

This study investigates and validates the use of the Octavius 4D system for patient specific quality assurance on Halcyon, which is capable of rotating at 4 revolutions per minute (RPM). A commercially available PTW Octavius 4D system was used for this study which had a maximum rotation speed of 3 RPM. Initial validation included testing the accuracy of the inclinometer, percent depth doses (PDD), output factors, and dose profiles for selected static square fields. The same static fields were also subject to a gamma comparison with the TPS. This was followed by an evaluation of twelve clinical treatment plans and seven non-clinical plans with varying gantry rotation speeds. All testing was completed using detector array measurement times of 200 ms and 100 ms. Inclinometer accuracy was within 0.3° of actual gantry angle. Output factors varied less than 0.6%, PDD differences were no greater than 1.4%, and dose profile differences were less than 2.2%. Gamma pass rates for the static fields were 96.7% (2%/2mm) and 99.7% (3%/3mm). A prototype control unit, which had a maximum rotation speed of 4 RPM was also used to test the clinical and non-clinical plans. For the clinical plans, the mean gamma pass rates (2%/2mm) were 86.1% and 88.1% for the commercial unit and prototype unit respectively. Results using a measurement time of 200 ms were superior to those using 100 ms. For Halcyon deliveries greater than 3 RPM, worst case gamma results for the commercial unit were 28.6% compared to 98.5% using the prototype unit. Accurate patient specific quality assurance results can be obtained using the Octavius 4D system with a Halcyon linac, provided that the system measurement time is kept at 200 ms and the rotation speed of Halycon does not exceed 3 RPM. For higher RPM deliveries, an Octavius 4D unit with 4 RPM rotation capability is recommended.

Dose verification of eye plaque brachytherapy using spectroscopic dosimetry.

Eye plaque brachytherapy has been developed and refined for the last 80 years, demonstrating effective results in the treatment of ocular malignancies. Current dosimetry techniques for eye plaque brachytherapy (such as TLD- and film-based techniques) are time consuming and cannot be used prior to treatment in a sterile environment. The measurement of the expected dose distribution within the eye, prior to insertion within the clinical setting, would be advantageous, as any errors in source loading will lead to an erroneous dose distribution and inferior treatment outcomes. This study investigated the use of spectroscopic dosimetry techniques for real-time quality assurance of I-125 based eye plaques, immediately prior to insertion. A silicon detector based probe, operating in spectroscopy mode was constructed, containing a small (1 mm(3)) silicon detector, mounted within a ceramic holder, all encapsulated within a rubber sheath to prevent water infiltration of the electronics. Preliminary tests of the prototype demonstrated that the depth dose distribution through the central axis of an I-125 based eye plaque may be determined from AAPM Task Group 43 recommendations to a deviation of 6 % at 3 mm depth, 7 % at 5 mm depth, 1 % at 10 mm depth and 13 % at 20 mm depth, with the deviations attributed to the construction of the probe. A new probe design aims to reduce these discrepancies, however the concept of spectroscopic dosimetry shows great promise for use in eye plaque quality assurance in the clinical setting.